Nootropics with evidence: every one ranked by its human trials
Reviewed 25 sourcesPublished by PepVault
Nootropics ranked by their human evidence: caffeine, creatine, bacopa, citicoline, ginkgo, omega-3, Semax and more, each with its best trial and effect size.

- Last reviewed
- Sources
- 25
- Questions
- 6
- Compounds
- 9
The short answer
Caffeine has the strongest human evidence: it reliably sharpens alertness, attention and reaction time. Creatine comes next: pooled trials found a memory gain, largest in older adults. Bacopa, L-theanine with caffeine, citicoline and ashwagandha have small positive trials. Ginkgo and omega-3 failed in large trials in older adults, and Semax, Selank and Cerebrolysin were tested mainly in patients, in Russia or by their makers.
Evidence: Ranges from many consistent human trials (caffeine) and meta-analyses with small, consistent effects (creatine, L-theanine with caffeine, bacopa) to single small or maker-run trials, results in patients only, and large trials that found no effect (ginkgo, omega-3).

Which nootropics have the best evidence?
A nootropic is anything taken to think better: sharper focus, better memory, less mental fatigue. The table ranks the ones people search by the best human evidence behind each, not by how often they are sold. Where a meta-analysis (pepvault.app/glossary/meta-analysis) pooled the trials, the effect is a standardized mean difference (SMD): the gap between the supplement and a placebo (pepvault.app/glossary/placebo) in units of the usual spread between people, where 0.2 is small, 0.5 medium and 0.8 large.
| Nootropic | Best human evidence | What it found | Grade |
|---|---|---|---|
| Caffeine | Review of the human trials1 | About 40 to 300 mg improved alertness, vigilance, attention and reaction time; memory and decision-making less consistently | Strong |
| Creatine | 16 trials, 492 adults2 | Memory SMD 0.31, moderate certainty by its authors; in healthy people, 0.88 at ages 66 to 76 and 0.03 at 11 to 313 | Moderate |
| L-theanine with caffeine | Meta-analysis of trials in healthy adults4 | Attention-switching accuracy SMD 0.33 in the second hour; most of the effect is caffeine's | Moderate, short-term |
| Bacopa monnieri | 9 trials, 518 people, 12 weeks or more5 | Faster on a trail-making test of attention switching and 10.6 ms faster choice reactions | Moderate, small effect |
| Citicoline | 100 adults aged 50 to 85 with age-related memory complaints, 500 mg a day for 12 weeks6 | Better episodic memory than placebo, in a trial run by the maker | Limited |
| Ashwagandha | 50 adults with mild cognitive impairment, 8 weeks8 | Better memory, attention and processing speed scores; for stress, 12 trials found a large but low-certainty drop9 | Limited |
| Magnesium L-threonate | 44 adults aged 50 to 70 with cognitive impairment, 12 weeks10 | Overall cognition up, effect size 0.91, in a trial run by its developer | Limited |
| Lion's mane | 30 adults aged 50 to 80 with mild cognitive impairment, 16 weeks11 | Cognitive scores rose against placebo and fell again 4 weeks after stopping | Limited |
| Rhodiola rosea | Review of 11 trials12 | 3 of 5 trials on mental fatigue were positive; every trial had a high or unclear risk of bias | Limited, contradictory |
| Panax ginseng | Cochrane review, 9 trials13 | Some measures improved; no convincing evidence of a benefit in healthy people | Limited |
| Phosphatidylserine | FDA's 2003 review of a health claim14 | A claim of lower dementia risk in the elderly is allowed only with FDA's disclaimer: the research is 'very limited and preliminary' and there is 'little scientific evidence supporting this claim' | Limited |
| Alpha-GPC | 261 people with Alzheimer's disease, 180 days15 | ADAS-Cog, where lower is better, fell 3.2 points on alpha-GPC and rose 2.9 on placebo; a treatment result in Alzheimer's, not a test in healthy people | Limited, patients only |
| Ginkgo biloba | 3,069 adults aged 72 to 96, about 6 years1617 | No fewer dementia cases and no slower decline in memory or attention | Failed in older adults |
| Omega-3 | Cochrane review, 3 trials, 3,536 older adults19 | No difference in cognition scores after 24 to 40 months | Failed in healthy older adults |
| Piracetam | Cochrane review in dementia20 | Better global impressions but no gain on any specific measure; the review does not support its use | Not supported |
The grades are ours. Strong means many trials agree in healthy people; moderate means a meta-analysis found a consistent effect; limited means one or two small trials, often run or paid for by the maker, or results in patients only; failed means a large, well-run trial found nothing. The deeper pages: L-theanine with caffeine and creatine beyond muscle each have their own guide, magnesium threonate is in our magnesium guide, and lion's mane has its own guide.
Add any supplement to your plan in PepVault, even one the library does not list, as an oral item with the time you take it; turn on its reminder and the app nudges you shortly after that time, and each day logs with one tap. Set reminders in PepVault

PepVault for iPhone
Keep your protocol in PepVault
Add any supplement to your plan in PepVault, even one the library does not list, as an oral item with the time you take it; turn on its reminder and the app nudges you shortly after that time, and each day logs with one tap.
7 days free on the yearly plan for new subscribers.
Which nootropics failed in large trials?
Ginkgo had one of the largest tests of any nootropic. The GEM trial gave 3,069 Americans aged 72 to 96 either 120 mg of ginkgo extract twice a day or a placebo and followed them for a median of 6.1 years1617. Dementia came at 3.3 cases per 100 person-years on ginkgo and 2.9 on placebo, a hazard ratio of 1.12 whose confidence interval (pepvault.app/glossary/confidence-interval) crossed 1, so no protection16. Yearly decline in memory, attention, language and executive function was the same in both groups17.
Ginkgo is not a total blank: in nine trials of 2,372 people who already had dementia, the extract EGb 761 beat placebo on cognition (SMD 0.58), with high variation between trials18. That is a treatment result in illness, not a gain for a healthy brain.
Omega-3 failed the same way. Three high-quality trials gave cognitively healthy people aged 60 and over fish-oil capsules or an omega-3 spread for 6 to 40 months. After 24 or 40 months, Mini-Mental State scores in two trials of 3,221 people matched placebo's (a mean difference of −0.07 points on a 30-point test), and in two trials of 1,043 people word learning, digit span and verbal fluency showed no benefit19. Omega-3 has its own case for the heart and blood fats at pepvault.app/peptides/omega-3-epa-dha. Piracetam rests on old dementia trials: pooled, more people on it were rated globally improved, but no specific test of memory or thinking moved, and the Cochrane reviewers concluded the evidence does not support its use20.
Why do nootropics work best in older adults?
Many of the positive trials enrolled people with room to improve. Creatine shows it most cleanly: in healthy people, memory rose by an SMD of 0.88 at ages 66 to 76 and by 0.03, effectively zero, at ages 11 to 313. The citicoline, ashwagandha, magnesium threonate and lion's mane trials all enrolled adults with memory complaints or mild cognitive impairment, and three of them took only people aged 50 or over681011. A rested, well-fed student near their own ceiling has less to gain, so a result in a 70-year-old with memory complaints does not carry over to a 25-year-old studying for exams.
Sleep loss is the other exception. The caffeine review singles out restricted sleep: for military, emergency and shift workers, repeated doses kept thinking and physical performance up1. If a nootropic seems to work best on a short night, that matches the trials. The compounds the library files under focus are at pepvault.app/peptides/for/focus-and-memory.
Do peptide nootropics like Semax, Selank and Cerebrolysin work?
These three have human trials, which most peptides lack, but none in healthy people trying to think better. Semax and Selank were developed and tested in Russia; Cerebrolysin is given as courses of daily infusions in many parts of the world24; none has FDA approval, and Drugs@FDA lists no application for any of them.
| Peptide | Best human evidence | What it found | Grade |
|---|---|---|---|
| Semax, a nasal spray | 110 patients recovering from stroke, Moscow, two 10-day courses21 | Blood BDNF, a brain growth factor, rose and stayed up; daily-living scores recovered faster; groups were not described as randomized | Limited, patients only |
| Selank, a nasal spray | 62 patients with anxiety or neurasthenia, against the tranquilizer medazepam22 | Calmed anxiety about as well as medazepam | Limited, anxiety only |
| Cerebrolysin, an IV infusion | 6 trials in Alzheimer's disease23; Cochrane review of 6 trials, 597 people with vascular dementia24 | Cognition better by an SMD of 0.40 at 4 weeks, not significant at 6 months23; better by 0.36, very low-quality evidence24 | Limited, patients only |
| Dihexa | No published human trial | Rat and mouse studies only; its developers' key paper on how it works was retracted in 202525 | None in people |
The Cerebrolysin meta-analysis included an author from its maker, and every Cochrane trial that reported its funding was paid for by industry2324; the full trial record, stroke included, is in our guide at pepvault.app/guides/cerebrolysin-explained, with the two reviews at pepvault.app/research/cerebrolysin-gauthier-2015 and pepvault.app/research/cerebrolysin-cui-2019. Semax and Selank each have a library page with their trials and the rat work behind them: pepvault.app/peptides/semax and pepvault.app/peptides/selank. Their effects on BDNF and nerve growth factor in the brain come from rats.
Commonly reported: with Semax, a quick lift in focus and mental energy within an hour, nasal stinging, and poor sleep when taken late; with Selank, a calmer, less tense feel without sedation, subtle for some.
How do you check a nootropic claim yourself?
- Find the trial behind the claim: a randomized trial (pepvault.app/glossary/randomized-controlled-trial) against a placebo, not a rat study, a test-tube study or a survey.
- Check who was tested. A result in older adults with memory complaints or in patients after a stroke says little about a healthy 30-year-old321.
- Count the people and the weeks. Fifty people for eight weeks8 is a pilot; 3,069 people for six years16 is an answer.
- Look for the effect size, not just 'significant': an SMD near 0.2 is small, 0.5 medium, 0.8 large.
- Read who paid. The citicoline, magnesium threonate and lion's mane trials were run by companies that make them61011.
- Check whether the effect held. Lion's mane scores fell within 4 weeks of stopping11, and Cerebrolysin's cognition gain was no longer significant at 6 months23.
PepVault's daily check-in lets you rate your energy, mood and sleep from 1 to 5 each day, so the days you took a supplement and the days you didn't are both on record. Log it in PepVault
Are nootropic supplements safe?
In the trials above, side effects mostly ran at placebo rates: ginkgo's adverse-effect profile matched placebo over six years16, citicoline's stroke trial found no difference in adverse events across 2,298 patients7, and omega-3's main side effect was a mild upset stomach, with fewer than 15% of people reporting any minor adverse event, as often on placebo19. Caffeine is the one with a clear ceiling; the FDA's 400 mg a day for most adults is in our L-theanine and caffeine guide.
When to get help If memory or concentration has been getting worse over months, or is affecting work or daily life, see a clinician: that is worth an assessment before any supplement.
Sources
- McLellan TM, Caldwell JA, Lieberman HR. A review of caffeine's effects on cognitive, physical and occupational performance. Neurosci Biobehav Rev. 2016. PubMed 27612937
- Xu C et al. The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis. Front Nutr. 2024. PubMed 39070254
- Prokopidis K et al. Effects of creatine supplementation on memory in healthy individuals: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2023. PubMed 35984306
- Payne ER et al. Effects of tea (Camellia sinensis) or its bioactive compounds l-theanine or l-theanine plus caffeine on cognition, sleep, and mood in healthy participants: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2025. PubMed 40314930
- Kongkeaw C et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014. PubMed 24252493
- Nakazaki E et al. Citicoline and memory function in healthy older adults: a randomized, double-blind, placebo-controlled clinical trial. J Nutr. 2021. PubMed 33978188
- Dávalos A et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012. PubMed 22691567
- Choudhary D, Bhattacharyya S, Bose S. Efficacy and safety of ashwagandha (Withania somnifera (L.) Dunal) root extract in improving memory and cognitive functions. J Diet Suppl. 2017. PubMed 28471731
- Akhgarjand C et al. Does ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022. PubMed 36017529
- Liu G et al. Efficacy and safety of MMFS-01, a synapse density enhancer, for treating cognitive impairment in older adults: a randomized, double-blind, placebo-controlled trial. J Alzheimers Dis. 2016. PubMed 26519439
- Mori K et al. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009. PubMed 18844328
- Ishaque S et al. Rhodiola rosea for physical and mental fatigue: a systematic review. BMC Complement Altern Med. 2012. PubMed 22643043
- Geng J et al. Ginseng for cognition. Cochrane Database Syst Rev. 2010. PubMed 21154383
- US Food and Drug Administration. Phosphatidylserine and cognitive dysfunction and dementia: qualified health claim letter of enforcement discretion. May 13, 2003 (archived). wayback.archive-it.org
- De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003. PubMed 12637119
- DeKosky ST et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008. PubMed 19017911
- Snitz BE et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA. 2009. PubMed 20040554
- Weinmann S et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010. PubMed 20236541
- Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev. 2012. PubMed 22696350
- Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001. PubMed 11405971
- Gusev EI et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PubMed 29798983
- Zozulia AA et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PubMed 18454096
- Gauthier S et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015. PubMed 25832905
- Cui S et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019. PubMed 31710397
- Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014. Retracted in 2025. PubMed 25187433
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.